Compare AMD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMD | NVO |
|---|---|---|
| Founded | 1969 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.4B | 203.2B |
| IPO Year | 2003 | 2001 |
| Metric | AMD | NVO |
|---|---|---|
| Price | $475.42 | $47.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 35 | 11 |
| Target Price | ★ $272.59 | $51.00 |
| AVG Volume (30 Days) | ★ 23.1M | 12.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | ★ 165.00 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.95 | N/A |
| Revenue Next Year | $43.19 | $3.70 |
| P/E Ratio | $205.86 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $149.22 | $35.12 |
| 52 Week High | $584.73 | $64.16 |
| Indicator | AMD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 54.56 |
| Support Level | $461.71 | $47.93 |
| Resistance Level | $561.27 | $50.45 |
| Average True Range (ATR) | 17.58 | 0.95 |
| MACD | -1.05 | 0.13 |
| Stochastic Oscillator | 39.76 | 94.29 |
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers (including artificial intelligence), industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. However, AMD is emerging as a prominent player in AI GPUs and related hardware. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.